Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
1,048 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06417814 | A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(TROPION-Lung15) | recruiting | Phase 3 | 744 | AstraZenecaINDUSTRY | 27 | May 14, 2026 | clinicaltrials |
| NCT07312786 | Testing the Feasibility of a Virtual Application to Support Breast and Colorectal Cancer Survivors | recruiting | N/A | 60 | Nova Scotia Health AuthorityOTHER |
| 1 |
| May 14, 2026 |
| clinicaltrials |
| NCT02333110 | GRID Therapy as Palliative Radiation for Patients With Advanced and Symptomatic Tumors | recruiting | N/A | 50 | Sir Mortimer B. Davis - Jewish General HospitalOTHER | 1 | May 12, 2026 | clinicaltrials |
| NCT00843375 | Evaluation of Stool Based Markers for the Early Detection of Colorectal Cancers and Adenomas | recruiting | — | 1,200 | University of Michigan Rogel Cancer CenterOTHER | 3 | May 11, 2026 | clinicaltrials |
| NCT04888481 | 68Ga-HA-DOTATATE Imaging of Suspected Somatostatin Receptor Positive Tumors | recruiting | Phase 2 | 600 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT05645510 | LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study(LONGEVITI) | recruiting | — | 75 | University of AlbertaOTHER | 1 | May 11, 2026 | clinicaltrials |
| NCT06697301 | Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | recruiting | Phase 2 / Phase 3 | 740 | Eikon TherapeuticsINDUSTRY | 24 | May 8, 2026 | clinicaltrials |
| NCT05601440 | Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer | recruiting | Phase 2 | 484 | Canadian Cancer Trials GroupNETWORK | 1 | May 7, 2026 | clinicaltrials |
| NCT06767306 | Stereotactic Ablative Radiotherapy (XRT) and Immunotherapy for Oligometastatic Extracranial Melanoma(AXIOM) | recruiting | Phase 2 | 129 | Melanoma Institute AustraliaOTHER | 2 | May 7, 2026 | clinicaltrials |
| NCT04610372 | 5500/20 vs. SABR or Brachytherapy for PRimary OligoMetastatic Prostate Cancer Treatment (PROMPT)(PROMPT) | recruiting | N/A | 168 | British Columbia Cancer AgencyOTHER | 1 | May 6, 2026 | clinicaltrials |
| NCT06898450 | A Study to Assess the Safety, Tolerability, and Efficacy of NDI-219216 in Patients With Advanced Solid Tumors. | recruiting | Phase 1 / Phase 2 | 134 | Nimbus Wadjet, Inc.INDUSTRY | 8 | May 6, 2026 | clinicaltrials |
| NCT07015190 | Neoadjuvant Darovasertib in Primary Uveal Melanoma | recruiting | Phase 3 | 520 | IDEAYA BiosciencesINDUSTRY | 21 | May 6, 2026 | clinicaltrials |
| NCT06319430 | Technology in Play for Children With Physical Disabilities: the Dice Model of Play | recruiting | N/A | 20 | University of ManitobaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT07366515 | Feasibility of a Multimodal Virtual Reality Intervention to Reduce Preoperative Anxiety in Cancer Surgery Patients | recruiting | N/A | 20 | University of ManitobaOTHER | 1 | May 5, 2026 | clinicaltrials |
| NCT01487603 | Feasibility of Evaluating Gene Alteration Analysis Using Samples Obtained by EBUS-TBNA in Patients With Lung Cancer | recruiting | — | 400 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT01786590 | Endobronchial Ultrasound-guided Transbronchial Needle Aspiration for Lymph Node Staging in Patients With Non-small Cell Lung Cancer Pursuing Stereotactic Body Radiotherapy (SBRT) | recruiting | N/A | 150 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT02732860 | Personalized Patient Derived Xenograft (pPDX) Modeling to Test Drug Response in Matching Host(REFLECT) | recruiting | — | 120 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT06193369 | Digital Peer Navigation for Adolescents and Young Adults With Cancer | recruiting | N/A | 138 | University Health Network, TorontoOTHER | 1 | May 4, 2026 | clinicaltrials |
| NCT03067051 | Clinical Study to Assess the Safety and Efficacy of the SpectraCure P18 System | recruiting | Phase 1 / Phase 2 | 66 | SpectraCure ABINDUSTRY | 4 | May 1, 2026 | clinicaltrials |
| NCT07016022 | Variability and Post-op AEs: Does Preoperative CardioPulmonary Variability Assessment Identify Risk of Postoperative Adverse Events Following Thoracic Surgery(CPVA) | recruiting | — | 130 | Ottawa Hospital Research InstituteOTHER | 1 | May 1, 2026 | clinicaltrials |
| NCT04256317 | A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study) | recruiting | Phase 2 / Phase 3 | 316 | Taiho Oncology, Inc.INDUSTRY | 10 | Apr 30, 2026 | clinicaltrials |
| NCT07024329 | Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)(RESPONd) | recruiting | N/A | 1,055 | University of CalgaryOTHER | 1 | Apr 30, 2026 | clinicaltrials |
| NCT06268405 | Positron Emission Mammography and Liquid Biopsy in Women With High-risk Breast Screenings | recruiting | N/A | 100 | University Health Network, TorontoOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07408063 | A Comprehensive Multiomic Biomarker Evaluation Across Two Single-arm Cohorts to Elucidate Mechanisms of Response and Resistance in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)(BeeHive) | recruiting | Phase 2 | 30 | University Health Network, TorontoOTHER | 1 | Apr 29, 2026 | clinicaltrials |
| NCT05023265 | Assessment of Quality of Life and Outcomes in Patients With Primary Renal Cell Carcinoma Treated With SBRT(AQuOS-II) | recruiting | N/A | 70 | Sunnybrook Health Sciences CentreOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT07446660 | STEP2 vs. Routine Early Palliative Care: Randomized Noninferiority Trial(STEP2 RNT) | recruiting | N/A | 652 | University Health Network, TorontoOTHER | 1 | Apr 28, 2026 | clinicaltrials |
| NCT06050694 | Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)(GRAIL) | recruiting | Phase 2 | 40 | University Health Network, TorontoOTHER | 1 | Apr 24, 2026 | clinicaltrials |
| NCT06816992 | ORIC-114 in Combination With Subcutaneous Amivantamab in Patients With EGFR Exon20 Insertion Mutant NSCLC | recruiting | Phase 1 | 76 | ORIC PharmaceuticalsINDUSTRY | 3 | Apr 24, 2026 | clinicaltrials |
| NCT04852887 | De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)(DEBRA) | recruiting | Phase 3 | 1,670 | NRG OncologyOTHER | 4 | Apr 23, 2026 | clinicaltrials |
| NCT04951804 | EUS-CPN With and Without Bupivacaine(EUS-NB) | recruiting | N/A | 180 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 23, 2026 | clinicaltrials |
| NCT05233397 | ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma | recruiting | Phase 2 | 30 | Nationwide Children's HospitalOTHER | 3 | Apr 23, 2026 | clinicaltrials |
| NCT03295981 | Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone | recruiting | Phase 3 | 120 | St. Louis UniversityOTHER | 3 | Apr 22, 2026 | clinicaltrials |
| NCT04959097 | Retinoblastoma Patient Clinical Database and Tissue Repository | recruiting | — | 800 | Children's Hospital Los AngelesOTHER | 2 | Apr 22, 2026 | clinicaltrials |
| NCT06599762 | Evaluation of Tranexamic Acid in Myelodysplastic Syndromes and Acute Myeloid Leukemia(MYELO-CAN:TXA) | recruiting | Phase 2 | 75 | University of ManitobaOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06707519 | NSCLC Liquid Biopsies and Exhaled VOC | recruiting | — | 210 | St. Joseph's Healthcare HamiltonOTHER | 1 | Apr 22, 2026 | clinicaltrials |
| NCT06532565 | Study of GS-2121 Given Alone or in Combination in Adults With Advanced Solid Tumors | recruiting | Phase 1 | 154 | Gilead SciencesINDUSTRY | 2 | Apr 21, 2026 | clinicaltrials |
| NCT06307795 | A Study to Investigate ANS014004 in Participants With Locally Advanced or Metastatic Solid Tumors | recruiting | Phase 1 | 63 | Avistone Biotechnology Co., Ltd.INDUSTRY | 3 | Apr 17, 2026 | clinicaltrials |
| NCT02468024 | JoLT-Ca Sublobar Resection (SR) Versus Stereotactic Ablative Radiotherapy (SAbR) for Lung Cancer(STABLE-MATES) | recruiting | Phase 3 | 272 | University of Texas Southwestern Medical CenterOTHER | 4 | Apr 16, 2026 | clinicaltrials |
| NCT05580562 | ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)(ACTION) | recruiting | Phase 3 | 510 | Jazz PharmaceuticalsINDUSTRY | 18 | Apr 16, 2026 | clinicaltrials |
| NCT06268626 | Detection of Endometrial Cancer Through Risk Modelling(DETECTR) | recruiting | — | 1,000 | University of British ColumbiaOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06439225 | Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes(OPTION-DDR) | recruiting | Phase 3 | 236 | Canadian Cancer Trials GroupNETWORK | 1 | Apr 16, 2026 | clinicaltrials |
| NCT06453486 | A Study of High Dose Radiation Therapy for Locally Advanced Pancreatic Cancer That Responded to Initial Chemotherapy Treatment(ABLATE) | recruiting | Phase 2 | 43 | University Health Network, TorontoOTHER | 1 | Apr 16, 2026 | clinicaltrials |
| NCT07528547 | Hypersight and Ethos In Pediatric Radiotherapy(Peds Ethos) | recruiting | N/A | 20 | University Health Network, TorontoOTHER | 1 | Apr 15, 2026 | clinicaltrials |
| NCT06235697 | Androgen Suppression Combined With Nodal Irradiation and Dose Escalated Prostate Treatment(ASCENDE-SBRT) | recruiting | Phase 3 | 710 | Canadian Cancer Trials GroupNETWORK | 2 | Apr 14, 2026 | clinicaltrials |
| NCT04686305 | Phase Ib Study of the Safety of T-DXd and Immunotherapy Agents With and Without Chemotherapy in Advanced or Metastatic HER2+, Non-squamous NSCLC(DL03) | recruiting | Phase 1 | 304 | AstraZenecaINDUSTRY | 19 | Apr 13, 2026 | clinicaltrials |
| NCT05465161 | STING MARK Universal Fiducial Marker System(StingMark) | recruiting | N/A | 100 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT06039111 | Indocyanine Green for Detection of Sentinel Lymph Nodes In Comparison to ICG Plus Technetium in the Evaluation of Vulvar Squamous Cell Carcinoma(IGNITE-V) | recruiting | — | 58 | Hamilton Health Sciences CorporationOTHER | 1 | Apr 13, 2026 | clinicaltrials |
Data updated 24 days agoSource updated unknownsource: clinicaltrials